

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P29875	Application No. 10/577,343
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		Applicant Yasuharu NISHIMURA et al.	
		I.A. Filing Date October 28, 2004	Group 1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/LB/	2006	0 2 5 1 6 6 6	11/09/06	NAKATSURA et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/LB/	1	English language abstract of EP0561183 (corresponding to JP 6-46882 A, published February 22, 1994), provided by esp@cenet.
/LB/	2	English language abstract of WO 95/29193 (corresponding to JP 10-505481, published June 2, 1998) and provided by esp@cenet.
/LB/	3	U.S. Patent Application 12/063,165 (NISHIMURA et al.) filed February 7, 2008, and entitled "Glypican-3 (GPC-3)-Derived Tumor Rejection Antigenic Peptides Useful for HLA-A2-Positive Patients and Pharmaceutical Comprising the Same."
/LB/	4	U.S. Patent Application 12/155,864 (NAKATSURA et al.) filed June 11, 2008, and entitled "Cancer Antigen and Use Thereof."
/LB/	5	U.S. Patent Application 11/577,435 (NISHIMURA et al.), filed April 18, 2007, and entitled "Novel Diagnostic Kit for Malignant Melanoma."

EXAMINER	/Lynn Bristol/	DATE CONSIDERED	04/15/2009
----------	----------------	-----------------	------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.